V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210031016 | 210021765 | 1.66 | 60.3 | Curative (C) | 2013-04-12 | 2013-05-19 | Imatinib 400mg | Y | N | 210033710 | IMATINIB |
| 210031017 | 210012233 | 1.84 | 26.3 | Curative (C) | 2014-06-04 | 2015-06-24 | ALL UKALL60+ TRIAL | Y | N | 210033717 | UKALL60+ |
| 210031018 | 210031276 | 1.64 | 86.3 | Palliative (P) | 2017-09-16 | 2017-09-16 | ALL UKALL60+ TRIAL | N | null | 210033742 | UKALL60+ |
| 210031019 | 210012239 | 1.6 | 59 | Curative (C) | 2015-09-10 | 2015-09-10 | Imatinib 200mg | N | N | 210033764 | IMATINIB |
| 210031020 | 210012245 | 1.77 | 70.2 | Disease modification (D) | 2014-01-13 | 2014-02-18 | CHLORAMBUCIL + OBINUTUZUMAB | N | N | 210033776 | CHLORAMBUCIL + OBINUTUZUMAB |
| 210031021 | 210012252 | null | 83.2 | Palliative (P) | 2015-05-12 | 2015-09-23 | IMATINIB | N | N | 210033792 | IMATINIB |
| 210031022 | 210012259 | 0 | 75.7 | Curative (C) | 2017-12-24 | 2018-02-22 | METHOTREXATE | N | Y | 210033811 | METHOTREXATE |
| 210031023 | 210012264 | null | 64.2 | Curative (C) | 2016-07-07 | 2016-09-06 | IDELALISIB + RITUXIMAB | N | N | 210033830 | IDELALISIB + RITUXIMAB |
| 210031024 | 210021784 | 1.68 | 99.7 | Neo-adjuvant (N) | 2016-04-22 | 2016-06-04 | Triple / Double Intrathecal Therapy | N | N | 210033831 | TRIPLE INTRATHECAL |
| 210031025 | 210021786 | null | 83.2 | null | 2015-07-23 | 2015-08-02 | Imatinib 600mg | Y | N | 210033839 | IMATINIB |
| 210031026 | 210012268 | 1.7 | null | Curative (C) | 2018-04-13 | 2018-04-13 | ALL UKALL60+ TRIAL | N | null | 210033851 | UKALL60+ |
| 210031027 | 210012272 | 1.78 | 114.1 | Curative (C) | null | 2017-03-01 | IMATINIB | N | null | 210033859 | IMATINIB |
| 210031028 | 210031282 | null | 16.3 | null | 2015-11-16 | 2015-11-23 | ALL UKALL60+ TRIAL | null | null | 210033868 | UKALL60+ |
| 210031029 | 210012277 | -1 | null | null | 2013-03-11 | 2013-06-18 | ALL UKALL2003 TRIAL | N | N | 210033900 | UKALL 2003 |
| 210031030 | 210012280 | 1.78 | 86.9 | Palliative (P) | null | 2015-08-19 | Chlorambucil + Pred + Rituximab | N | N | 210033901 | CHLORAMBUCIL + RITUXIMAB |
| 210031031 | 210012288 | null | null | Curative (C) | 2018-05-27 | 2018-05-27 | HYDROCORTISONE IT + METHOTREXATE IT | N | N | 210033953 | METHOTREXATE |
| 210031032 | 210012292 | 0 | 57.9 | Palliative (P) | 2019-03-22 | 2019-03-23 | IMATINIB | N | N | 210033985 | IMATINIB |
| 210031033 | 210021806 | 1.73 | 62 | Adjuvant (A) | 2018-05-23 | 2018-10-26 | ALL UKALL2003 TRIAL | 02 | N | 210034017 | UKALL 2003 |
| 210031034 | 210021808 | 1.81 | 113.95 | Disease modification (D) | 2014-08-17 | 2014-08-29 | Imatinib 600mg | 02 | N | 210034019 | IMATINIB |
| 210031035 | 210012300 | 1.83 | 77.9 | Disease modification (D) | 2016-09-22 | 2016-10-26 | CHLORAMBUCIL + RITUXIMAB | N | N | 210034037 | CHLORAMBUCIL + RITUXIMAB |
| 210031036 | 210012310 | 1.71 | 72.4 | Palliative (P) | 2017-09-03 | 2017-09-03 | Triple Intrathecal | N | N | 210034070 | TRIPLE INTRATHECAL |
| 210031037 | 210012313 | 1.61 | null | Disease modification (D) | 2015-06-24 | 2015-07-16 | Triple / Double Intrathecal Therapy | N | N | 210034090 | TRIPLE INTRATHECAL |
| 210031038 | 210027696 | 0 | 82 | Disease modification (D) | 2017-06-24 | 2017-12-24 | Imatinib 600mg | N | N | 210034098 | IMATINIB |
| 210031039 | 210012316 | 1.55 | 80 | Disease modification (D) | 2017-10-03 | 2017-12-05 | Imatinib 400mg | Y | N | 210034099 | IMATINIB |
| 210031040 | 210035077 | 1.67 | 81.4 | Disease modification (D) | 2017-03-04 | 2017-05-28 | ALL UKALL60+ TRIAL | 01 | N | 210034115 | UKALL60+ |
| 210031041 | 210012324 | 1.59 | 44 | Palliative (P) | 2018-10-02 | 2018-10-03 | Imatinib 400mg | N | N | 210034118 | IMATINIB |
| 210031042 | 210027702 | 0 | 103.4 | Curative (C) | 2017-09-07 | 2018-04-06 | IMATINIB | N | N | 210034139 | IMATINIB |
| 210031043 | 210021826 | 1.66 | 99.8 | Palliative (P) | 2016-03-09 | 2016-03-09 | METHOTREXATE | N | N | 210034157 | METHOTREXATE |
| 210031044 | 210027704 | 1.79 | 58 | Disease modification (D) | 2019-07-29 | 2019-08-04 | Imatinib 400mg | 2 | N | 210034173 | IMATINIB |
| 210031045 | 210012336 | null | null | Palliative (P) | 2018-04-20 | 2018-04-20 | ALL UKALL2003 TRIAL | N | N | 210034178 | UKALL 2003 |
| 210031046 | 210033549 | 1.5 | 66 | Curative (C) | 2013-10-25 | 2014-03-11 | ALL UKALL60+ TRIAL | 02 | N | 210034183 | UKALL60+ |
| 210031047 | 210012339 | 1.74 | 12.7 | Adjuvant (A) | null | 2018-09-11 | IDELALISIB + RITUXIMAB | Y | N | 210034234 | IDELALISIB + RITUXIMAB |
| 210031048 | 210012345 | 1.51 | 59.7 | Curative (C) | 2017-02-05 | 2017-04-06 | CHLORAMBUCIL + OBINUTUZUMAB | N | N | 210034306 | CHLORAMBUCIL + OBINUTUZUMAB |
| 210031049 | 210012350 | null | 72 | Curative (C) | 2017-07-20 | 2017-09-15 | ALL UKALL2003 TRIAL | N | N | 210034345 | UKALL 2003 |
| 210031050 | 210012352 | 1.65 | 29.65 | Curative (C) | 2017-01-01 | 2017-01-01 | Triple Intrathecal | N | null | 210034354 | TRIPLE INTRATHECAL |
| 210031051 | 210012356 | null | null | Palliative (P) | 2016-02-09 | 2016-04-12 | Imatinib 400mg | 02 | null | 210034361 | IMATINIB |
| 210031052 | 210021842 | 1.7 | 76.4 | Disease modification (D) | 2014-05-04 | 2014-05-04 | R Chlorambucil | 2 | N | 210034369 | CHLORAMBUCIL + RITUXIMAB |
| 210031053 | 210021843 | 1.69 | 87.9 | Curative (C) | 2014-03-23 | 2014-03-23 | ALL UKALL2003 TRIAL | N | N | 210034384 | UKALL 2003 |
| 210031054 | 210031301 | 1.6 | 65.75 | Curative (C) | 2013-07-09 | 2013-07-22 | Triple / Double Intrathecal Therapy | N | null | 210034437 | TRIPLE INTRATHECAL |
| 210031055 | 210012364 | 0 | 60 | Curative (C) | 2019-02-05 | 2019-03-15 | ALL UKALL60+ TRIAL | N | N | 210034490 | UKALL60+ |
| 210031056 | 210012365 | 1.75 | 84 | Disease modification (D) | 2018-02-16 | 2018-05-19 | IMATINIB | 02 | N | 210034498 | IMATINIB |
| 210031057 | 210012370 | 1.73 | 73 | Palliative (P) | 2015-09-17 | 2015-11-06 | IDELALISIB + RITUXIMAB | 2 | N | 210034516 | IDELALISIB + RITUXIMAB |
| 210031058 | 210012376 | 1.77 | 85.9 | Curative (C) | 2018-09-21 | 2018-12-07 | METHOTREXATE | 02 | N | 210034526 | METHOTREXATE |
| 210031059 | 210012379 | null | 100.5 | Disease modification (D) | 2016-08-07 | 2016-08-07 | ALL UKALL60+ TRIAL | N | N | 210034566 | UKALL60+ |
| 210031060 | 210012380 | 1.79 | 57.8 | Palliative (P) | 2016-06-02 | 2016-06-13 | Triple Intrathecal | N | N | 210034567 | TRIPLE INTRATHECAL |
| 210031061 | 210027725 | 1.74 | 55 | Palliative (P) | null | 2017-09-07 | ALL UKALL60+ TRIAL | Y | N | 210034577 | UKALL60+ |
| 210031062 | 210012385 | 1.79 | 116.5 | Curative (C) | 2014-10-31 | 2015-01-09 | IDELALISIB + RITUXIMAB | 02 | N | 210034596 | IDELALISIB + RITUXIMAB |
| 210031063 | 210012388 | 1.67 | 52.5 | Disease modification (D) | 2017-10-07 | 2017-10-07 | Imatinib 600mg | N | N | 210034609 | IMATINIB |
| 210031064 | 210033558 | 0 | null | Disease modification (D) | 2013-10-14 | 2013-10-26 | METHOTREXATE | null | null | 210034652 | METHOTREXATE |
| 210031065 | 210037855 | 1.8 | 110 | null | 2017-07-04 | 2017-08-01 | IDELALISIB + RITUXIMAB | 02 | N | 210034666 | IDELALISIB + RITUXIMAB |